CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
2.201
-0.109 (-4.73%)
Jan 22, 2025, 2:10 PM EST - Market open
CERO Employees
As of December 31, 2023, CERo Therapeutics Holdings had 9 total employees, including 8 full-time and 1 part-time employees.
Employees
9
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$609,795
Market Cap
4.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
CERO News
- 6 weeks ago - CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO - GlobeNewsWire
- 2 months ago - CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia - GlobeNewsWire
- 2 months ago - CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity - GlobeNewsWire
- 3 months ago - CERo Therapeutics, Inc. Provides Corporate Update - GlobeNewsWire
- 4 months ago - CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer - GlobeNewsWire
- 4 months ago - Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump - Benzinga
- 4 months ago - CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 - GlobeNewsWire
- 6 months ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July - Benzinga